Results 201 to 210 of about 262,063 (357)

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga   +8 more
wiley   +1 more source

Nature of phantoms

open access: bronze, 1978
Theodore L. Dorpat
openalex   +1 more source

OXA-48-like carbapenemases: the phantom menace.

open access: yesJournal of Antimicrobial Chemotherapy, 2012
L. Poirel, A. Potron, P. Nordmann
semanticscholar   +1 more source

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

open access: yesMolecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy   +9 more
wiley   +1 more source

Development of a deep learning based approach for multi-material decomposition in spectral CT: a proof of principle in silico study. [PDF]

open access: yesSci Rep
Rajagopal JR   +11 more
europepmc   +1 more source

Improved cardiac anthropomorphic phantom. [PDF]

open access: bronze, 1994
Stephen W. Smith   +3 more
openalex   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

open access: yesMolecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern   +7 more
wiley   +1 more source

The Production and Evaluation of the Tissue-equivalent Phantom for the Magnetic Resonance Imaging [PDF]

open access: green, 1994
Young Hoon Ryu   +4 more
openalex   +1 more source

Home - About - Disclaimer - Privacy